Treatment Information

Back

Prostate Cancer treatment details. Chemotherapy, Hormone.

Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, United Kingdom.

Survival: monthsCountry:United Kingdom
Toxiciy Grade:5City/State/Province:Sutton, Surrey
Treatments:Chemotherapy, HormoneHospital:Royal Marsden NHS Foundation Trust and The Institute of Cancer Research
Drugs:Journal:Link
Date:Oct 2010

Description:

Patients:
This phase 3 study involved men with metastatic castration-resistant prostate cancer. Patients were separated into two treatment groups. Group A consisted of 377 men with a median age of 67 years and a range of 61-72. Group B included 378 men with a median age of 68 years and a range of 62-73.

Treatment:
Patients in group A were given the hormone prednisone (to act as an anti-inflammatory medication) along with the chemotherapy agent mitoxantrone, which targets DNA replication to block cancer cell growth.

Patients in group B were given the hormone prednisone and the chemotherapy agent cabazitaxel, which is a microtubule-stabilizer that blocks division (growth) of cancer cells.

Toxicities:
Three deaths due to adverse events were reported for group A. Causes included neutropenia/sepsis, cardiac event, and motor vehicle accident. Neutropenia (58% of patients), leucopenia (42%), and anemia (5%) were the most common toxicities of grade 3 or higher.

In group B, 18 deaths due to adverse events were reported. Causes included neutropenia/sepsis, cardiac events, dehydration/electrolyte imbalance due to diarrhea, renal failure, and cerebral hemorrhage.

Results:
Median progression-free survival for group A (mitoxantrone) was 1.4 months and median overall survival was 12.7 months.

For group B (cabazitaxel), the median progression-free survival was 2.8 months and the median overall survival was 15.1 months.

Support:
This study was funded by Sanofi-Aventis, makers of mitoxantrone.

Correspondence: Dr. Johann Sebastian de Bono; email: [email protected]



Back